Oesophageal intestinal metaplasia

Digestive and Liver Disease

Volumn 32, Issue 5, 2000, Pages 367-371

  Tytgat, G N J ^a   van Sandick, J W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ARTICLE; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CARDIA; COST EFFECTIVENESS ANALYSIS; DYSPLASIA; EARLY DIAGNOSIS; ENDOSCOPY; ESOPHAGUS; ESOPHAGUS CANCER; HISTOLOGY; HUMAN; INTESTINE METAPLASIA; LASER COAGULATION; METAPLASIA; PHOTODYNAMIC THERAPY; PRECANCER;

EID: 0033853380     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1590-8658(00)80254-6     Document Type: Article

References (65)

1. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
2. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction
3. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease
4. Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux
5. Adenocarcinoma and Barrett's esophagus. An overrated risk?
6. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus
7. Barrett's esophagus: Development of dysplasia and adenocarcinoma
8. Barrett's esophagus. Prevalence and incidence of adenocarinoma
9. Length of Barrett's oesophagus: An important factor in the development of dysplasia and adenocarcinoma
10. Surgical therapy in Barrett's esophagus
11. Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus
12. Surgical treatment of Barrett's carcinoma. Correlations between morphologic findings and prognosis
13. The spectrum of columnar-lined esophagus-Barrett's esophagus
14. Early diagnosis of columnar-lined esophagus: A new endoscopic diagnostic criterion
15. Endoscopic diagnosis of columnar-lined esophagus
16. The diagnosis of Barrett's esophagus: Goblets, goblets
17. Short Barrett: Prevalence and risk factors
18. Barrett's esophagus, dysplasia, and adenocarcinoma
19. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy
20. Short segment Barrett's esophagus: Clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia
21. Endoscopic features of the columnar-lined esophagus
22. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus
23. Flow-cymetric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort
24. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence
25. The neoplastic potential of columnar-lined (Barrett's) esophagus
26. Barrett's esophagus: Development of dysplasia and adenocarcinoma
27. Methylene blue-directed biopsy for improved detection of intestinal metaplasia and dysplasia in Barrett's esophagus: A controlled sequential trial
28. Esophageal cancer: Screening and surveillance. Results of a consensus conference held at the VIth World Congress of the International Society for Diseases of the Esophagus
29. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus
30. Histopathologic characteristics of early adenocarcinoma in Barrett's esophagus
31. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions
32. Observer variation in the diagnosis of dysplasia in Barrett's esophagus
33. Adenocarcinoma in Barrett's esophagus. A clinico-pathologic study of 65 cases
34. Barrett's esophagus with high-grade dysplasia: An induction for esophagectomy?
35. Surgical management of high-grade dysplasia in Barrett's esophagus
36. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia
37. High-grade dysplasia in the columnar-lined esophagus
38. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy
39. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: A review
40. An endoscopic biopsy protocol can differentiate high grade dysplasia from early adenocarcinoma in Barrett's esophagus
41. Summary of a working party on the surveillance of premalignant lesions
42. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma
43. Eradication of Barrett's mucosa with argon plasma coagulation and acid supression: Immediate and mid term results
44. Photodynamic therapy for Barrett's esophagus: Follow-up in 100 patients
45. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid
46. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: A review
47. Regression of Barrett's esophagus: The role of acid suppression, surgery, and ablative methods
48. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression
49. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects
50. Endoscopic surveillance of patients with Barrett esophagus
51. Oesophageal cancer is an uncommon cause ofdeath in patients with Barrett's oesophagus
52. Cost effectiveness of detecting Barrett's cancer
53. Endoscopic surveillance of Barrett's esophagus: A cost-effectiveness comparison with screening mammography
54. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk
55. A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting
56. Barrett's esophagus
57. A guide for surveillance of patients with Barrett's esophagus
58. Endoscopic surveillance of Barrett's esophagus. Does it help?
59. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients
60. Basic issues in population screening for cancer
61. Lead time gained by diagnostic screening for breast cancer
62. Theory of early detection of breast cancer in the general population